AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$21.03 USD
+0.66 (3.24%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $21.02 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANAB 21.03 +0.66(3.24%)
Will ANAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANAB
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
ANAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
Other News for ANAB
AnaptysBio (ANAB) Target Price Raised by Wedbush | ANAB Stock News
AnaptysBio price target raised by $5 at Wedbush, here's why
Analyst Expectations For AnaptysBio's Future
Notable Two Hundred Day Moving Average Cross - ANAB
AnaptysBio GAAP EPS of -$1.34 beats by $0.21, revenue of $22.26M beats by $10.58M